The 2025 Guangzhou Unicorn Innovation Enterprise List was officially released recently. Guangzhou Laien Biological Medicine Co., Ltd., a leading enterprise深耕 (deeply engaged) in the field of mRNA-encoded TCR-T cell therapy, once again ranked on the "Future Unicorn" innovation enterprise list due to its continuously breakthrough technical strength and strong growth potential.This honor is not only an authoritative recognition of Laien Bio's annual innovation achievements, but also confirms its leading value as a benchmark for Sino-Singapore cell therapy cooperation.

This list was guided by the Guangzhou Science and Technology Bureau, hosted by the Guangzhou Association of Science and Technology Innovation Enterprises, and jointly released by the Guangzhou Industrial Development Research Institute and the Guangzhou Association of Science and Technology Innovation Enterprises. It serves as an important showcase of the achievements in the tiered cultivation of innovative enterprises in Guangzhou. The "Future Unicorn" group for 2025 grew by 4% compared to last year, with the biopharmaceutical field becoming one of the core tracks, boasting 38 listed companies. This sector highlights innovation vitality in cutting-edge areas such as gene therapy and cell therapy. Guangzhou Laien Biological Medicine Co., Ltd. stood out among numerous candidates with its steadily growing market expectations, continuously advancing R&D pipeline, and breakthrough progress in international multicenter clinical trials, achieving an honorable consecutive win.

After retaining the title of "Future Unicorn," Guangzhou Laien Biological Medicine Co., Ltd. will enjoy an upgraded empowerment service system in Guangzhou. On the capital front, it can access more precise industrial funds and cross-border financing resources, injecting new momentum into technology transformation; regarding IPO cultivation, customized guidance from the Southern Center of the Shanghai Stock Exchange will accelerate its process of going public; in terms of industrial synergy, it will be deeply integrated into Guangzhou's biomedicine industry cluster, co-building an innovative ecosystem with leading enterprises; additionally, one-stop support such as direct policy access, industry-university-research collaboration, and brand matrix promotion will comprehensively boost the company’s development.

Lion TCR, a clinical-stage biotech company incubated by Singapore's Agency for Science, Technology and Research (A*STAR), has once again demonstrated its strong capabilities in the field of cell therapy with this latest recognition. The company’s core product—an mRNA-encoded TCR-T cell therapy targeting the hepatitis B virus (HBV)—is not onlyThe World's FirstThe same therapy approved by the FDA for an international multicenter Phase II liver cancer clinical trial, supported by both Fast Track and Orphan Drug designations, has recently successfully obtained FDA approval to expand its indications to the treatment of chronic hepatitis B. The IND tacit approval granted by the Chinese NMPA in November 2024 marks a key phase in the clinical advancement of this therapy in China.

Driven by technological innovation, Laien Bio is accelerating the construction of a research and development matrix that covers multiple scenarios. Leveraging an AI-driven TCR novel target discovery platform and core RNA technology, the company's R&D pipeline has successfully expanded from its stronghold in liver cancer to high-incidence solid tumors such as lung cancer and breast cancer. More importantly, it has proactively laid out plans for in vivo TCR-T universal cell therapy. This innovative therapy not only significantly reduces treatment costs but also holds the potential to make cutting-edge cell therapy accessible to a broader patient population. Currently, its HBV-targeting in vivo TCR-T therapy has demonstrated remarkable efficacy in animal models, laying a solid foundation for subsequent industrial transformation.

Standing at a New Starting Point of Repeated Honors, Guangzhou Laien Biological Medicine Co., Ltd. will Leverage the Resource Empowerment of a "Future Unicorn" to Further Bridge the Gap Between Capital and R&D. In the Future, the Company Will Accelerate the Clinical Progress of Its Core Pipeline, Focusing on Breaking Through the Industrialization Bottleneck of in vivo TCR-T Universal Cell Therapy. With Safer, More Efficient, and More Accessible Innovative Therapies, It Aims to Bring New Hope to Cancer and Infectious Disease Patients in China and Globally. Meanwhile, Aligned with National Strategies and Guangzhou's "12218" Modern Industrial System Construction, the Company Will Add Greater Weight to Guangzhou’s Biomedical Industry as a "Hard Technology" Benchmark.

Highlights:

Guangzhou Laien Biological Medicine Co., Ltd. and SIAT Sign Cooperation Framework Agreement to Jointly Develop In Vivo Universal Cell Therapy Technology

World's First! Laien Bio's mRNA-Encoded TCR-T Approved for Clinical Trials, Precisely Targeting Hepatocellular Carcinoma

LIONTCR

WeChat ID｜Laien Bio

Official Website｜https://www.liontcr.com/